MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses
Authors' conclusion
These data demonstrate effective glycemic control with the MM780G system on days when some users did not initiate boluses. A greater proportion of real-world users achieved glycemic goals when ROS were used.
Study context
- Population
- Consenting MM780G users, global CareLink data uploaded 2 January 2020 to 31 March 2025, with ≥10 days without any user-initiated bolusesof 369,467 users
- Participants
- 54,553 users
- Exposure
- Recommended optimal settings (ROS) use vs non-ROS use on days without user-initiated boluses
- Outcome
- Glycemic metrics on days when boluses were missed
Methodological detailsglobal CareLink personal data
- Global CareLink personal data
Main finding
As reported in the abstract
Mean TIR
Mean TBR
Mean GMI
mg/dL
| Outcome | ROS | Non-ROS |
|---|---|---|
| Mean SG | 149.2 | 159.7 |
Observational data: associations, not effects.
Original publication
MiniMed 780G Advanced Hybrid Closed-Loop System Use During Days Without User-Initiated Boluses. Diabetes Care. Published 7 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →